Stay up-to-date with our latest news

🚨 Regulation Alert in the Research World! 🚨 Buckle up—Europe is moving full speed ahead! 🔹 CTR NEWSFLASH FAST-EU is here, marking a major leap toward faster, more coordinated trial assessments across Europe. Translation: ➡️ quicker study start-ups, ➡️ smoother review processes, ➡️ bringing innovative therapies to patients sooner. With Europe’s optimized timelines, highly engaged sites, and Ad Hoc Clinical's excellent support during start-up and monitoring, there’s never

Day 2 at BIO Europe in Vienna — what an energizing ride! From reconnecting with familiar faces to meeting so many new ones (including a few who, it turns out, live just around the corner — who knew we had to come all the way to Vienna to meet?! 😄). It’s always amazing how big this world feels… and yet how small it really is. We wrapped up the day in true Viennese style — at the Imperial Palace, of course — and let’s just say it wouldn’t be Vienna if we hadn’t dared to dust o

Kicking off BIO-Europe 2025 in Vienna in style! After an energizing stroll along the beautiful Danube — yes, it’s not quite as blue as the song promised 😉 — Our CEO, Evelyne Vermeersch, dove straight into prospecting at the exhibition hall. Proud to see Ad Hoc Clinical, your trusted partner for Regulatory Affairs and Clinical Research Monitoring in Europe, shining bright at the Belgian booth! A big shoutout to FIT - Flanders Investment & Trade, Biovia, Wallonia Export & Inv

Our CEO Evelyne Vermeersch is thrilled to represent Ad Hoc Clinical at hashtag#BioEurope 2025 in Vienna! From 3–5 November, She’ll join industry leaders and innovators, connecting with everyone who shares the passion for advancing clinical research across Europe. At Ad Hoc Clinical, we provide expert clinical services in: ✅ Regulatory Affairs – navigating European requirements with precision ✅ Clinical Monitoring – guaranteeing the highest standards of quality, compliance, an

From clinical insights to candlelit conversations! Last week, our CEO, Evelyne Vermeersch, joined the Healixia Clinical Conference, followed by the BioWin Annual Dinner — a day where sharp minds met forward-thinking moves – and the future felt a little closer! 🧭 Major topic of the day? Belgium is stepping up. Starting January 1, 2026, initial applications for mononational Phase I–II trials will be assessed within 20 days, and Phase II/III–IV trials within 35 days (provided n

🚀 Big news from Belgium: clinical trial approvals go into fast-forward! Starting1 January 2026, the Belgian Federal Agency for Medicines and Health Products (FAMHP) will cut clinical trial approval timelines in half — positioning Belgium among the fastest regulators! These accelerated timelines will allow clinical research to start sooner, bringing innovative treatments faster to patients, without compromising on quality or safety. 💡 Why does this matter? With these new tim